Alpha glucosidase inhibitors market to reach $7.05 billion by 2030

By AI, Created 10:11 AM UTC, May 20, 2026, /AGP/ – The global alpha glucosidase inhibitors market is projected to grow from $5.19 billion in 2026 to $7.05 billion by 2030 as diabetes rates rise and treatment options expand. North America leads the market now, while the Middle East is expected to be the fastest-growing region.

Why it matters: - Rising diabetes rates are expanding demand for drugs that help control post-meal blood sugar spikes. - The market’s projected growth signals stronger use of alpha glucosidase inhibitors in type 2 diabetes prevention and management. - The report points to broader shifts toward combination therapies, digital monitoring, and more personalized treatment.

What happened: - The Business Research Company released its Global Market Report 2026 for alpha glucosidase inhibitors on May 7, 2026. - The market is forecast to grow from $4.84 billion in 2025 to $5.19 billion in 2026. - The report projects the market will reach $7.05 billion by 2030. - North America was the largest regional market in 2025. - The Middle East is expected to be the fastest-growing region over the forecast period.

The details: - Alpha glucosidase inhibitors slow carbohydrate absorption in the intestines. - The drugs help delay or prevent type 2 diabetes in people with impaired glucose tolerance. - The class is especially useful for patients at risk of hypoglycemia or lactic acidosis. - The market’s recent growth is linked to higher type 2 diabetes prevalence, an aging population, government awareness programs, limited access to advanced therapies in developing regions, and more research activity. - The report’s forecast growth is supported by new drug formulations, wider use of combination therapies, more investment in digital health tracking, broader online pharmacy access, and progress in precision medicine. - The report highlights personalized diabetes treatment, low-glycemic diet therapies, safer medications that avoid hypoglycemia, expanded combination therapy use, and patient-centered digital health platforms as key trends. - The National Health Service in the UK reported in June 2024 that more than 549,000 additional people in England were identified as at risk for type 2 diabetes in 2023. - The NHS said the number of people with pre-diabetes registered with general practitioners rose to 3,615,330 from 3,065,825 in 2022, an increase of nearly 20%. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Between the lines: - The market forecast reflects a broader shift from treating diabetes only after diagnosis to managing earlier risk and progression. - Growth in online pharmacies and digital health tools suggests distribution and adherence are becoming part of the treatment story, not just the drug itself. - The regional split suggests mature demand in North America and faster expansion in markets where diabetes burden is rising and access is improving.

What’s next: - The market is expected to keep accelerating through 2030 as combination therapies and precision medicine gain traction. - Competition will likely intensify around safer, more personalized products and digital tools that support long-term glucose management. - The Business Research Company also points readers to a free sample of the report and the full market report.

The bottom line: - Rising diabetes prevalence is keeping alpha glucosidase inhibitors on a growth path, with the market set to expand steadily through 2030.